The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index; none of the 49 sources its claims cite is checked for support yet.
Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death
Open accessAbstract
The correlation between telomerase activity and human tumors has led to the hypothesis that tumor growth requires reactivation of telomerase and that telomerase inhibitors represent a class of chemotherapeutic agents. Herein, we examine the effects of inhibition of telomerase inside human cells. Peptide nucleic acid and 2′ -O- MeRNA oligomers inhibit telomerase, leading to progressive telomere shortening and causing immortal human breast epithelial cells to undergo apoptosis with increasing frequency until no cells remain. Telomere shortening is reversible: if inhibitor addition is terminated, telomeres regain their initial lengths. Our results validate telomerase as a target for the discovery of anticancer drugs and supply general insights into the properties that successful agents will require regardless of chemical type. Chemically similar oligonucleotides are in clinical trials and have well characterized pharmacokinetics, making the inhibitors we describe practical lead compounds for testing for an antitelomerase chemotherapeutic strategy.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
Inhibiting telomerase in immortal human cells with 2′-O-MeRNA or PNA oligonucleotides caused progressive telomere shortening, apoptosis, and eventual loss of proliferation. Telomere shortening and growth arrest were reversible when inhibitor treatment was stopped.
Key findings
- Complementary 2′-O-MeRNA inhibited >95% of telomerase activity 1 day after transfection and >70% at 3 days. HME50-5E proliferation slowed after 15–25 days, and no treated cells remained after 110 days; apoptosis rose from <5% during the first 60 days to 14% at 80 days and 56% at 100 days, versus 2–3% in controls.
- DU145 cells began slowing after 60 days and had undergone 20 fewer population doublings than mismatch-treated cells by 120 days. HME50-hTERT cells, with longer telomeres, showed no significant growth reduction over 120 days.
- Mean telomere restriction fragment length decreased from 2,000 to 1,700 bp in HME50-5E cells by 60 days, from 3,600 to 2,200 bp in DU145 cells by 76 days, and from 7,600 to 6,800 bp in HME50-hTERT cells after 75 days. A template-directed PNA inhibited >90% of telomerase activity at 1 day and shortened telomeres, whereas a nontemplate PNA inhibited only 50% and did not shorten telomeres.
- After inhibitor withdrawal at 76 days, eroded telomeres returned to approximately initial lengths within 3 weeks, and previously static HME50-5E cells regained growth within 3 weeks. No evidence for an ALT pathway was observed.
Methods
- Immortal human cell lines HME50-5E, DU145, and HME50-hTERT were transfected with 2′-O-MeRNA or PNA/DNA complexes using cationic lipids; treatment was repeated every 3–4 days for 120 days, with mismatch oligomers, lipid alone, or nontemplate PNA as controls.
- Telomerase activity was measured by TRAP, mean telomere length by telomere restriction fragment Southern analysis, apoptosis by Annexin V flow cytometry, and proliferation by cell counts/population doublings.
- Effects of matched versus mismatched or nontemplate inhibitors were compared over time to test sequence-specific, telomerase-dependent mechanisms.
Limitations
- Stated in the paper: the TRF assay does not monitor subtelomeric erosion and may underestimate total telomeric DNA loss; 5–30% of telomerase activity remained after treatment; systemic telomerase inhibition would also affect normal stem cells; the long lag before phenotypic effects complicates drug development; and no ALT pathway was observed in these cell types, leaving applicability to ALT-positive tumors uncertain.
- Evident from the text: findings are in vitro in a small number of immortal cell lines, including p53-mutant lines, with no animal or human efficacy/toxicity data; the 120-day culture experiments required stringent precautions against contamination but remain vulnerable to long-term culture artifacts.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
32 Not checked yet · 31 Own result · 28 Own interpretation · 5 No basis given · 2 Own method
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and this percentage increased to 56% after 100 days”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Within 60 days of treatment, the mean telomere length of HME50-5E cells treated with 2′-O-MeRNA complementary to hTR was reduced from 2,000 to 1,700 bp (Fig. 4a).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“leading to progressive telomere shortening”
- Also stated in: § Abstract · plain
“cause telomeres to shorten”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The growth of cells treated with the control oligomer containing mismatch bases was not affected.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“By 80 days, however, 14% of cells treated with the match oligomer were observed to undergo apoptosis”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Peptide nucleic acid and 2′-O-MeRNA oligomers inhibit telomerase”
- Also stated in: § Abstract · plain
“We observe that 2′-O-MeRNA and peptide nucleic acid (PNA) oligomers complementary to the template region of hTR inhibit telomerase”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“By the end of the experiment (after 120 days), these cells had undergone 20 fewer population doublings than had cells treated with mismatch-containing oligomer.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“By contrast, cells treated with lipid alone or the 2′-O-MeRNA oligomer containing mismatched bases underwent apoptosis at a rate of 2–3% throughout the entire experiment.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“HME50-hTERT cells have a much longer mean TRF length (7.6 kilobases) than either HME50-5E or DU145 cells”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Telomere shortening is reversible: if inhibitor addition is terminated, telomeres regain their initial lengths.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
- It may state two separate claims as one. 14
- Probably not a substantial claim. 23
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The TRF length of cells treated with 2-O-MeRNA containing mismatches relative to hTR remained at 2,000 bp, and the signal intensity of probe hybridization was undiminished.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We observe telomere shortening and decreased cell proliferation, even though between 5% and 30% of telomerase activity remained after treatment with inhibitor.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Telomerase activity has been found in almost all human tumors but not in adjacent normal cells (3, 4).”
What the sources say
- Not checked yetcites [3] Kim N W, Piatyszek M A, Prowse K R, Harley C B, West M D, Ho P L C, Coviello G M, Wright W E, Weinrich S L, Shay J W. Science. 1994;266:2011–2015. doi: 10.1126/science.7605428. [DOI] [PubMed] [Google Scholar] source
- Not checked yetcites [4] Counter C M, Hirte H W, Bachetti S, Harley C B. Proc Natl Acad Sci USA. 1994;91:2900–2904. doi: 10.1073/pnas.91.8.2900. [DOI] [PMC free article] [PubMed] [Google Scholar] source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Human telomerase is a ribonucleoprotein that adds repeated units of TTAGGG to the ends of telomeres (1, 2).”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“The levels of telomerase activity were within the linear range of the TRAP assay (40).”
What the sources say
- Not checked yetcites [40] Holt S E, Norton J C, Wright W E, Shay J W. Methods Cell Sci. 1996;18:237–248. [Google Scholar] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“or tumor aggressiveness (11, 12).”
What the sources say
- Not checked yetcites [11] Ohyashiki J H, Ohyashiki K, Iwama I, Hayashi S, Toyama K, Shay J W. Clin Cancer Res. 1997;3:619–625. [PubMed] [Google Scholar]
- Not checked yetcites [12] Hoos A, Hepp H H, Kaul S, Ahlert T, Bastert G, Wallwiener D. Int J Cancer. 1998;79:8–12. doi: 10.1002/(sici)1097-0215(19980220)79:1<8::aid-ijc2>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“recent reports of the effect of the mTR deletion in different genetic backgrounds (17, 18) suggest that the role of telomerase in cancer development could be highly context dependent (19).”
What the sources say
- Not checked yetcites [17] Greenberg R, Chin L, Femino A, Lee K, Gottlieb G J, Greider C W, DePinho R A. Cell. 1999;97:515–525. doi: 10.1016/s0092-8674(00)80761-8. [DOI] [PubMed] [Google Scholar] source
- Not checked yetcites [18] Chin L, Artandi S E, Shen Q, Tam A, Lee S L, Gottlieb G J, Greider C W, DePinho R A. Cell. 1999;97:527–538. doi: 10.1016/s0092-8674(00)80762-x. [DOI] [PubMed] [Google Scholar] source
- Not checked yetcites [19] de Lange T, Jacks T. Cell. 1999;98:273–275. doi: 10.1016/s0092-8674(00)81955-8. [DOI] [PubMed] [Google Scholar] source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The cells divide normally until telomeres shorten sufficiently to affect proliferation. At this stage, most cells die”
What the sources say
- Not checked yetcites [31] Lunblad V, Blackburn E H. Cell. 1993;73:347–360. doi: 10.1016/0092-8674(93)90234-h. [DOI] [PubMed] [Google Scholar] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“expression of telomerase in conjunction with expression of simian virus 40 large T oncoprotein and an oncogenic allele of H-ras has been shown to promote tumorigenic conversion of normal human cells (28).”
What the sources say
- Not checked yetcites [28] Hahn W C, Counter C M, Lundberg A S, Beijersbergen R L, Brooks M W, Weinberg R A. Nature (London) 1999;400:464–468. doi: 10.1038/22780. [DOI] [PubMed] [Google Scholar] source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“whereas the late-stage disease has high telomerase activity and correlates with a poor outcome (6).”
What the sources say
- Not checked yetcites [6] Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek M A, Shay J W. Nat Med. 1995;1:249–255. doi: 10.1038/nm0395-249. [DOI] [PubMed] [Google Scholar] source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This decrease in measured TRF length may be an underestimate of the total loss of chromosomal DNA, because the TRF assay does not monitor erosion of subtelomeric regions and because relatively little telomeric DNA remained to hybridize with radiolabeled probe.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The 2′-O-MeRNA inhibitor contained four phosphorothioate linkages, a chemical moiety noted for its propensity to produce misleading cellular effects that seem sequence-specific but are actually unrelated to binding to the intended target (42).”
What the sources say
- Not checked yetcites [42] Stein C A. Antisense Res Dev. 1997;7:207–209. [Google Scholar]
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, the lack of telomerase expression seems to curb growth of rapidly proliferating cells eventually, whereas an increase in telomerase permits indefinite proliferation.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Mutation of the RNA component of telomerase of Tetrahymena (20), Kluyveromyces lactis (21), Saccharomyces cerevisiae (22)”
What the sources say
- Not checked yetcites [20] Yu G-L, Bradley J D, Attardi L D, Blackburn E H. Nature (London) 1990;344:126–132. doi: 10.1038/344126a0. [DOI] [PubMed] [Google Scholar] source
- Not checked yetcites [21] McEachern M J, Blackburn E H. Nature (London) 1995;376:403–409. doi: 10.1038/376403a0. [DOI] [PubMed] [Google Scholar] source
- Not checked yetcites [22] Singer M S, Gottschling D E. Science. 1994;266:404–409. doi: 10.1126/science.7545955. [DOI] [PubMed] [Google Scholar] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, although telomerase activity can confer extended life span to cells, other mechanisms may also exist.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Telomerase will be an unusually challenging target for drug development because of the long lag period expected before telomeres would shorten sufficiently to produce detrimental effects on cell growth and because of the possibility of alternate mechanisms for maintenance of telomeres.”
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“other studies have suggested that telomerase activity is correlated with the pathologic stage (8–11)”
What the sources say
- Not checked yetcites [8] Albanell J, Lonardo F, Rusch V, Engelhardt M, Langenfeld J, Han W, Klimstra D, Venkatraman E, Moore M A S, Dmitrovsky E. J Natl Cancer Inst. 1997;89:1609–1615. doi: 10.1093/jnci/89.21.1609. [DOI] [PubMed] [Google Scholar] source
- Not checked yetcites [9] Tahara H, Kuniyasu H, Yokozaki H, Yasui W, Shay J W, Ide T, Tahara E. Clin Cancer Res. 1995;1:1245–1251. [PubMed] [Google Scholar]
- Not checked yetcites [10] Engelhardt M, Drullinsky P, Guillem J, Moore M A. Clin Cancer Res. 1997;3:1931–1941. [PubMed] [Google Scholar]
- Not checked yetcites [11] Ohyashiki J H, Ohyashiki K, Iwama I, Hayashi S, Toyama K, Shay J W. Clin Cancer Res. 1997;3:619–625. [PubMed] [Google Scholar]
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“but some rare survivors continue to proliferate through a recombination mechanism to maintain telomere length.”
What the sources say
- Not checked yetcites [31] Lunblad V, Blackburn E H. Cell. 1993;73:347–360. doi: 10.1016/0092-8674(93)90234-h. [DOI] [PubMed] [Google Scholar] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“a few rare tumors (29) and some experimentally immortalized cell lines (30) lack detectable telomerase activity.”
What the sources say
- Not checked yetcites [29] Gupta J, Han L P, Wang P, Bacchetti S. J Natl Cancer Inst. 1996;88:1152–1157. doi: 10.1093/jnci/88.16.1152. [DOI] [PubMed] [Google Scholar] source
- Not checked yetcites [30] Bryan T M, Englezou A, Dalla-Pozza L, Dunham M A, Reddel R R. Nat Med. 1997;3:1271–1274. doi: 10.1038/nm1197-1271. [DOI] [PubMed] [Google Scholar] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“To confirm that the effects of inhibitor addition were reproducible, treatment of HME50-5E cells with 2′-O-MeRNA was repeated, and a similar decrease in proliferation was observed.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Because of the extreme length of these experiments, stringent precautions were taken to avoid contamination of cultured cells, and all experiments were completed successfully without interruption.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Recent work with PNAs introduced into cells by electroporation has shown decreased cell viability, supporting our findings (49).”
What the sources say
- Not checked yetcites [49] Shammas M A, Simmons C S, Corey D R, Shmookler-Reis R J. Oncogene. 1999;18:6191–6200. doi: 10.1038/sj.onc.1203069. [DOI] [PubMed] [Google Scholar] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This inhibition may result in few side effects, because the relatively short telomeres of tumors may erode to a critical length before irreversible harm is done to other cells.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Telomerase is an ideal target for oligonucleotides, because its RNA template is essential for activity and is intrinsically accessible to binding by nucleic acids.”
- Also stated in: § Discussion · plain
“The exposed RNA template of hTR makes telomerase an ideal target for oligonucleotides”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Also stated in: § Discussion · plain
None of the sources cited for this claim have been checked yet.
In the paper
“In addition, 2′-O-MeRNA and other 2′-O-alkyl-derivatized oligomers bind more tightly to complementary RNA sequences than do analogous DNA oligomers”
What the sources say
- Not checked yetcites [45] Agrawal S, Jiang Z, Zhao Q, Shaw D, Cai Q, Roskey A, Channavajjala L, Saxinger C, Zhang R. Proc Natl Acad Sci USA. 1997;94:2620–2625. doi: 10.1073/pnas.94.6.2620. [DOI] [PMC free article] [PubMed] [Google Scholar] source
- Not checked yetcites [46] Zhou W, Agrawal S. Bioorg Med Chem Lett. 1998;8:3269–3274. doi: 10.1016/s0960-894x(98)00591-5. [DOI] [PubMed] [Google Scholar] source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Systemic administration of telomerase inhibitors will also inhibit telomerase in normal stem cells.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“Oligonucleotides are being tested in 13 ongoing clinical trials (43)”
What the sources say
- Not checked yetcites [43] Hogrefe R I. Antisense Nucleic Acid Drug Dev. 1999;9:351–357. doi: 10.1089/oli.1.1999.9.351. [DOI] [PubMed] [Google Scholar] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Tu et al. (47) have performed a comprehensive survey of the literature, leading Stein (48) to estimate that non-sequence-selective effects may be at least partially implicated in results reported in 94% of the 2,026 studies published through 1997.”
What the sources say
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“and have improved resistance to degradation by nucleases, reducing the need for phosphorothioate linkages and improving the selectivity of antisense effects (45, 46)”
What the sources say
- Not checked yetcites [45] Agrawal S, Jiang Z, Zhao Q, Shaw D, Cai Q, Roskey A, Channavajjala L, Saxinger C, Zhang R. Proc Natl Acad Sci USA. 1997;94:2620–2625. doi: 10.1073/pnas.94.6.2620. [DOI] [PMC free article] [PubMed] [Google Scholar] source
- Not checked yetcites [46] Zhou W, Agrawal S. Bioorg Med Chem Lett. 1998;8:3269–3274. doi: 10.1016/s0960-894x(98)00591-5. [DOI] [PubMed] [Google Scholar] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Indeed, we have previously observed that oligonucleotides that contain uniform phosphorothioate oligonucleotides inhibit telomerase in a non-sequence-specific fashion, presumably through binding to hTERT (38).”
What the sources say
- Not checked yetcites [38] Pitts A E, Corey D R. Proc Natl Acad Sci USA. 1998;95:11549–11554. doi: 10.1073/pnas.95.20.11549. [DOI] [PMC free article] [PubMed] [Google Scholar] source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“one oligonucleotide, Fomivirsen, has been approved for the treatment of cytomegalovirus retinitis (44).”
What the sources say
- Not checked yetcites [44] Marwick C. J Am Med Assoc. 1998;280:871. [Google Scholar] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
The mice used in these experiments possessed much longer telomeres than those found in cancerous human cells.
“the mice used in these experiments possessed much longer telomeres than those found in cancerous human cells”
The paper relies on this without support.
Chemically similar oligonucleotides are in clinical trials and have well characterized pharmacokinetics.
“Chemically similar oligonucleotides are in clinical trials and have well characterized pharmacokinetics”
The paper relies on this without support.
HME50-5E cells were derived from HME50 preimmortal cells that had one mutant p53 allele and lost the second allele during spontaneous immortalization.
“HME50-5E cells were derived from HME50 preimmortal cells that had one mutant p53 allele and lost the second allele during spontaneous immortalization”
The paper relies on this without support.
DU145 cells have two mutant p53 alleles.
“whereas DU145 cells have two mutant alleles”
The paper relies on this without support.
The genetic background of HME50-hTERT cells is similar to that of HME50-5E cells.
“even though the genetic background of HME50-hTERT cells is similar to that of HME50-5E cells”
The paper relies on this without support.
HME50-5E cells have shorter telomeres than DU145 cells.
“which have shorter telomeres than DU145 cells”
The paper relies on this without support.
HME50-hTERT cells have an initial telomere length approximately 4,000 bp longer than that of HME50-5E cells.
“their initial telomere length of HME50-hTERT cells is approximately 4,000 bp longer.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In contrast to previous results employing anti-sense oligonucleotides or the expression of dominant-negative hTERT alleles (Hahn et al., 1999b;Herbert et al., 1999;Zhang et al., 1999) we saw no evidence for an increased rate of apoptosis in the inhibitor-treated cells.”
From A highly selective telomerase inhibitor limiting human cancer cell proliferation (2001) · cites this paper as Herbert et al., 1999
In the citing paper
“Induction of ALT has also never been reported in previous publications using other means of telomerase inhibition (Hahn et al., 1999b;Herbert et al., 1999;Zhang et al., 1999).”
From A highly selective telomerase inhibitor limiting human cancer cell proliferation (2001) · cites this paper as Herbert et al., 1999
In the citing paper
“Several strategies to inhibit telomerase activity have been reported.These include peptide nucleic acids and 2¢-O-MeRNA oligonucleotides directed towards the telomerase RNA template (Herbert et al., 1999), compounds that target telomeric DNA such as cationic porphyrins or anthraquinones (Sun et al., 1997) and nucleosidic reverse transcriptase inhibitors (Strahl and Blackburn, 1996).”
From A highly selective telomerase inhibitor limiting human cancer cell proliferation (2001) · cites this paper as Herbert et al., 1999
Citations
Cites
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091
Self-citationExtension of Life-Span by Introduction of Telomerase into Normal Human Cells
Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C.-P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S., & Wright, W. E. (1998) · Science · doi:10.1126/science.279.5349.349 · Cited by 4,975
Self-citationSequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide
Nielsen, P. E., Egholm, M., Berg, R. H., & Buchardt, O. (1991) · Science · doi:10.1126/science.1962210 · Cited by 3,332
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
The RNA Component of Human Telomerase
Feng, J., Funk, W. D., Wang, S.-S., Weinrich, S. L., Avilion, A. A., Chiu, C.-P., Adams, R. R., Chang, E., Allsopp, R. C., Yu, J., et al. (1995) · Science · doi:10.1126/science.7544491 · Cited by 2,227
Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA
Blasco, M. A., Lee, H.-W., Hande, M. P., Samper, E., Lansdorp, P. M., DePinho, R. A., & Greider, C. W. (1997) · Cell · doi:10.1016/s0092-8674(01)80006-4 · Cited by 2,108
Morin, G. B. (1989) · Cell · doi:10.1016/0092-8674(89)90035-4 · Cited by 1,495
Longevity, Stress Response, and Cancer in Aging Telomerase-Deficient Mice
Rudolph, K. L., Chang, S., Lee, H.-W., Blasco, M., Gottlieb, G. J., Greider, C., & DePinho, R. A. (1999) · Cell · doi:10.1016/s0092-8674(00)80580-2 · Cited by 1,349
Bryan, T. M., Englezou, A., Dalla-Pozza, L., Dunham, M. A., & Reddel, R. R. (1997) · Nature Medicine · doi:10.1038/nm1197-1271 · Cited by 1,292
Essential role of mouse telomerase in highly proliferative organs
Lee, H.-W., Blasco, M. A., Gottlieb, G. J., Horner, J. W., Greider, C. W., & DePinho, R. A. (1998) · Nature · doi:10.1038/33345 · Cited by 1,270
Research works printed but not linked: 5
- H Tahara, H Kuniyasu, H Yokozaki, W Yasui, J W Shay, T Ide, E Tahara Clin Cancer Res 1, 1245–1251 (1995).
- M Engelhardt, P Drullinsky, J Guillem, M A Moore Clin Cancer Res 3, 1931–1941 (1997).
- J H Ohyashiki, K Ohyashiki, I Iwama, S Hayashi, K Toyama, J W Shay Clin Cancer Res 3, 619–625 (1997).
- J W Shay, D Brasiskyte, M Ouellette, M A Piatyszek, H Werbin, Y Ying, W E Wright Methods Mol Genet 5, 263–268 (1994).
- C A Stein Antisense Res Dev 7, 207–209 (1997).
Cited by
Sorted by citations
Items 201–300 of 541
Inhibition of telomerase by BIBR 1532 and related analogues
Barma, D. K., Elayadi, A. N., Falck, J. R., & Corey, D. R. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00101-x · Cited by 52
Self-citationIkeda, N., Uemura, H., Ishiguro, H., Hori, M., Hosaka, M., Kyo, S., Miyamoto, K., Takeda, E., & Kubota, Y. (2003) · PubMed · Cited by 52
Tripathi, S. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki743 · Cited by 51
Herbert, B., Wright, A., Passons, C., Wright, W. E., Ali, I., Kopelovich, L., & Shay, J. W. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.1.39 · Cited by 51
Self-citationThe Role of Telomerase Expression and Telomere Length Maintenance in Human and Mouse
Nan-PIng, W., & Hodes, R. J. (2000) · Journal of Clinical Immunology · doi:10.1023/a:1017223602293 · Cited by 49
Physical activity, a modulator of aging through effects on telomere biology
Semeraro, M. D., Smith, C., Kaiser, M., Levinger, I., Duque, G., Gruber, H. J., & Herrmann, M. (2020) · Aging · doi:10.18632/aging.103504 · Cited by 50
Use of Telomerase to Create Bioengineered Tissues
Shay, J. W., & Wright, W. E. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1356.037 · Cited by 49
Self-citationTichy, E. D., Sidibe, D. K., Tierney, M. T., Stec, M. J., Sharifi‐Sanjani, M., Hosalkar, H. S., Mubarak, S. J., Johnson, F. B., Sacco, A., & Mourkioti, F. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.08.003 · Cited by 49
Purbhoo, M. A., Li, Y., Sutton, D. H., Brewer, J. E., Emma Gostick, D., Bossi, G., Laugel, B., Moysey, R. K., Baston, E., Liddy, N., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0092 · Cited by 47
Recent advances in the development of peptide nucleic acid as a gene-targeted drug
Marin, V. L., Roy, S., & Armitage, B. A. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.3.337 · Cited by 47
Liver cell specific targeting of peptide nucleic acid oligomers
Zhang, X., Simmons, C. G., & Corey, D. R. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00198-6 · Cited by 47
Self-citationTárkányi, I., & Aradi, J. (2007) · Biochimie · doi:10.1016/j.biochi.2007.09.002 · Cited by 48
Molecular targeting of cancer: Telomeres as targets
Hodes, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151267698 · Cited by 47
Liu, W., Jiang, J.-F., Xiao, D., & Ding, J. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01424-7 · Cited by 47
Telomerase and cancer: time to move from a promising target to a clinical reality
Keith, W. N., Evans, T. R. J., & Glasspool, R. M. (2001) · The Journal of Pathology · doi:10.1002/path.1001 · Cited by 47
Universal tumor antigens as targets for immunotherapy
Gordan, J. D., & Vonderheide, R. H. (2002) · Cytotherapy · doi:10.1080/146532402760271091 · Cited by 46
Replicative senescence and senescence-like state induced in cancer-derived cells
Hwang, E. S. (2002) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(02)00102-1 · Cited by 45
Antitumor Activity of Systemically Delivered Ribozymes Targeting Murine Telomerase RNA
Nosrati, M., Li, S., Bagheri, S., Ginzinger, D. G., Blackburn, E. H., Debs, R. J., & Kashani–Sabet, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0134 · Cited by 45
Eitsuka, T., Nakagawa, K., Suzuki, T., & Miyazawa, T. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2005.08.017 · Cited by 45
Increase of telomerase activity and hTERT expression in myelodysplastic syndromes
Briatore, F., Barrera, G., Pizzimenti, S., Toaldo, C., Casa, C. D., Laurora, S., Pettazzoni, P., Dianzani, M. U., & Ferrero, D. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.10.8130 · Cited by 45
4-Hydroxynonenal inhibits telomerase activity and hTERT expression in human leukemic cell lines
Pizzimenti, S., Briatore, F., Laurora, S., Toaldo, C., Maggio, M., Grandi, M. D., Meaglia, L., Menegatti, E., Giglioni, B., Dianzani, M. U., et al. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.12.024 · Cited by 45
Analysis of Telomerase in Candida albicans : Potential Role in Telomere End Protection
Singh, S. M., Steinberg‐Neifach, O., Mian, S. I., & Lue, N. F. (2002) · Eukaryotic Cell · doi:10.1128/ec.1.6.967-977.2002 · Cited by 44
Telomerase: biology and phase I trials
Kèlland, L. R. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00226-6 · Cited by 44
Islam, B., Stadlbauer, P., Gil-Ley, A., Pérez‐Hernández, G., Haider, S. M., Neidle, S., Bussi, G., Banáš, P., Otyepka, M., & Šponer, J. (2017) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.7b00226 · Cited by 43
Synthesis of distamycin A polyamides targeting G-quadruplex DNA
Moore, M. M., Cuenca, F., Searcey, M., & Neidle, S. (2006) · Organic & Biomolecular Chemistry · doi:10.1039/b607707b · Cited by 43
Dettler, J. M., Buscaglia, R., Cui, J., Cashman, D. J., Blynn, M., & Lewis, E. A. S. (2010) · Biophysical Journal · doi:10.1016/j.bpj.2010.04.042 · Cited by 43
Nakamura, M., Nabetani, A., Mizuno, T., Hanaoka, F., & Ishikawa, F. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.24.11073-11088.2005 · Cited by 44
Lavanya, C., Venkataswamy, M. M., Sibin, M. K., Bharath, M. M. S., & Chetan, G. K. (2018) · Cytotechnology · doi:10.1007/s10616-018-0205-9 · Cited by 41
Kim, Y. H., & Park, T. J. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.1.295 · Cited by 42
Telomerase as a Growth-Promoting Factor
Gorbunova, V. A., & Seluanov, A. (2003) · Cell Cycle · doi:10.4161/cc.2.6.515 · Cited by 42
Subramanian, L., Moser, B. A., & Nakamura, T. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01614-07 · Cited by 41
Delhommeau, F., Thierry, A., Feneux, D., Lauret, E., Leclercq, E., Courtier, M. H., Sainteny, F., Vainchenker, W., & Griscelli, A. B. (2002) · Oncogene · doi:10.1038/sj.onc.1206054 · Cited by 42
Sun, D., Zhang, R., Yuan, F., Liu, D., Zhou, Y., & Liu, J. (2011) · Dalton Transactions · doi:10.1039/c1dt11676b · Cited by 40
The Emerging Role of Telomerase in Cardiac Muscle Cell Growth and Survival
Oh, H., & Schneider, M. D. (2002) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.2002.2018 · Cited by 40
Telomerase inhibitors: targeting the vulnerable end of cancer?
Kèlland, L. R. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200008000-00001 · Cited by 40
Chen, C., Chang, D., Chen, T., Lee, C.-C., Hsieh, H.-H., Huang, F.-C., Huang, K.-F., Guh, J., Lin, J., & Huang, H. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.11.032 · Cited by 39
Administration of a Nucleoside Analog Promotes Cancer Cell Death in a Telomerase-Dependent Manner
Zeng, X., Hernandez-Sanchez, W. M., Xu, M., Whited, T. L., Baus, D., Zhang, J., Berdis, A. J., & Taylor, D. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.020 · Cited by 39
Zaffaroni, N., Lualdi, S., Villa, R., Bellarosa, D., Cermele, C., Felicetti, P., Rossi, C., Orlandi, L., & Daidone, M. G. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00139-9 · Cited by 40
Telomerase confers resistance to caspase-mediated apoptosis
Bermudez, Y., Erasso, D. M., Johnson, N. C., Matte, M. Y. A.-D., Lowell, N. E., & Kruk, P. A. (2006) · Clinical Interventions in Aging · doi:10.2147/ciia.2006.1.2.155 · Cited by 39
Compton, S. A., Elmore, L. W., Haydu, K., Jackson‐Cook, C. K., & Holt, S. E. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1452-1462.2006 · Cited by 41
Cappello, V., Tramontano, A. L., & Koch, U. (2002) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.10070 · Cited by 39
Moorhouse, A. D., Haider, S. M., Gunaratnam, M., Munnur, D., Neidle, S., & Moses, J. E. (2008) · Molecular BioSystems · doi:10.1039/b801822g · Cited by 38
Gene Delivery to Mammalian Cells
Heiser, W. C. (2003) · Humana Press eBooks · doi:10.1385/1592596509 · Cited by 38
Telomerase inhibition and the future management of head-and-neck cancer
McCaul, J. A., Gordon, K., Clark, L., & Parkinson, E. K. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00729-5 · Cited by 39
Nafee, N. A., Schneider, M., Friebel, K., Dong, M., Schaefer, U. F., Mürdter, T. E., & Lehr, C. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.11.019 · Cited by 37
Gavory, G. (2002) · Nucleic Acids Research · doi:10.1093/nar/gkf575 · Cited by 41
The Pleiotropy of Telomerase against Cell Death
Sung, Y. H., Choi, Y. S., Cheong, C., & Lee, H. (2005) · Molecules and Cells · doi:10.1016/s1016-8478(23)13173-6 · Cited by 37
Role of Telomerase in the Cardiovascular System
Zurek, M., Altschmied, J., Kohlgrüber, S., Ale‐Agha, N., & Haendeler, J. (2016) · Genes · doi:10.3390/genes7060029 · Cited by 39
Allsopp, R., Cheshier, S. H., & Weissman, I. L. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20021003 · Cited by 37
Boklan, J., Nanjangud, G. J., MacKenzie, K. L., May, C., Sadelain, M., & Moore, M. A. S. (2002) · PubMed · Cited by 37
Telomerase as a new target for the treatment of hormone-refractory prostate cancer
Biroccio, A., & Leonetti, C. (2004) · Endocrine Related Cancer · doi:10.1677/erc.1.00764 · Cited by 37
Telomerase and Telomeres: From Basic Biology to Cancer Treatment
Helder, M. N., Wisman, G. B. A., & van der Zee, A. G. J. (2002) · Cancer Investigation · doi:10.1081/cnv-120000370 · Cited by 37
15d-PGJ2 is a new hope for controlling tumor growth.
Bie, Q., Dong, H., Jin, C., Zhang, H., & Zhang, B. (2018) · PubMed · Cited by 36
Khaw, A. K., Silasudjana, M., Banerjee, B., Suzuki, M., Baskar, R., & Hande, M. P. (2007) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2007.06.005 · Cited by 36
Natarajan, S., Chen, Z., Wancewicz, E. V., Monia, B. P., & Corey, D. R. (2004) · Oligonucleotides · doi:10.1089/oli.2004.14.263 · Cited by 36
Self-citationMethods for assessing DNA hybridization of peptide nucleic acid–titanium dioxide nanoconjugates
Brown, E. M. B., Paunesku, T., Wu, A., Thurn, K. T., Haley, B., Clark, J., Priester, T., & Woloschak, G. E. (2008) · Analytical Biochemistry · doi:10.1016/j.ab.2008.08.020 · Cited by 36
Dong, M., Philippi, C., Loretz, B., Nafee, N. A., Schaefer, U. F., Friedel, G., Ammon-Treiber, S., Griese, E., Lehr, C., Klotz, U. E., et al. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.07.009 · Cited by 36
Telomerase inhibitors for the treatment of cancer: the current perspective
Perry, P. J., Arnold, J. R. P., & Jenkins, T. C. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.12.2141 · Cited by 36
D, R. P. M., Sorrentino, A., Pierconti, F., Maggiano, N., Faggi, R., Montano, N., Maira, G., Larocca, L. M., Levi, A., & Falchetti, M. L. (2005) · International Journal of Cancer · doi:10.1002/ijc.21613 · Cited by 35
Peptide Nucleic Acids, Morpholinos and Related Antisense Biomolecules
Janson, C. G., & During, M. J. (2006) · Springer eBooks · doi:10.1007/0-387-32956-0 · Cited by 35
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Matera, L. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.11.002 · Cited by 34
Role of Pin2/TRF1 in telomere maintenance and cell cycle control
Zhou, X. Z., Perrem, K., & Lu, K. P. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10496 · Cited by 34
Martí‐Centelles, R., Falomir, E., Murga, J., Cardá, M., & Marco, J. A. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.09.014 · Cited by 33
Deeb, D., Gao, X., Liu, Y., Kim, S.-H., Pindolia, K. R., Arbab, A. S., & Gautam, S. C. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.05.024 · Cited by 33
YANG, K. Y., Zheng, D., Deng, X., Bai, L., Xu, Y., & Cong, Y. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21919 · Cited by 33
POT1 Association with TRF2 Regulates Telomere Length
Kendellen, M. F., Barrientos, K. S., & Counter, C. M. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00286-09 · Cited by 34
Long non-coding RNAs at work on telomeres: Functions and implications in cancer therapy
Gala, K., & Khattar, E. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.036 · Cited by 34
Aquilanti, E., Kageler, L., Watson, J., Baird, D. M., Jones, R. E., Hodges, M., Szegletes, Z. M., Doench, J. G., Strathdee, C. A., McFaline-Figueroa, J. R., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad024 · Cited by 33
Synergy Between 3′Azido-3′deoxythymidine and Paclitaxel in Human Pharynx FaDu Cells
Johnston, J. S., Johnson, A. D., Gan, Y., Wientjes, M. G., & Au, J. L. ‐. (2003) · Pharmaceutical Research · doi:10.1023/a:1024431218327 · Cited by 33
Brassat, U., Balabanov, S., Bali, D., Dierlamm, J., Braig, M., Hartmann, U., Sirma, H., Güneş, Ç., Wege, H., Fehse, B., et al. (2010) · Experimental Hematology · doi:10.1016/j.exphem.2010.10.001 · Cited by 34
Allosteric inhibitors of telomerase: oligonucleotide N3'->P5' phosphoramidates
Pruzan, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.2.559 · Cited by 33
Dynamics of telomere erosion in transformed and non-transformed avian cells in vitro
Swanberg, S. E., & Delany, M. E. (2003) · Cytogenetic and Genome Research · doi:10.1159/000075769 · Cited by 33
Beisner, J., Dong, M., Taetz, S., Nafee, N. A., Griese, E., Schaefer, U. F., Lehr, C., Klotz, U. E., & Mürdter, T. E. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.07.010 · Cited by 33
Liu, W., Sun, D., & Hurley, L. H. (2005) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770500267238 · Cited by 34
Yang, D., & Sheu, S. (2007) · The Journal of Physical Chemistry A · doi:10.1021/jp071963o · Cited by 32
Brandt, S., Heller, H., Schuster, K., & Grote, J. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00887.x · Cited by 32
Chen, X., Zha, G., Wang, J. Q., & Liu, X. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1484735 · Cited by 33
Telomerase inhibitors in cancer therapy: current status and future directions.
Incles, C. M., Schultes, C. M., & Neidle, S. (2003) · PubMed · Cited by 32
Role of hTERT in apoptosis of cervical cancer induced by histone deacetylase inhibitor
Wu, P., Li, M., Wang, H., Zhou, J., Xu, G., Wang, S., Xi, L., Chen, G., Wang, B., Zhu, T., et al. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.039 · Cited by 32
Inhibition of telomerase by linear-chain fatty acids: a structural analysis
Oda, M., Ueno, T., Kasai, N., Takahashi, H., Yoshida, H., Sugawara, F., Sakaguchi, K., Hayashi, H., & Mizushina, Y. (2002) · Biochemical Journal · doi:10.1042/bj20021089 · Cited by 32
Fatemi, A., Safa, M., & Kazemi, A. (2015) · Tumor Biology · doi:10.1007/s13277-015-3575-z · Cited by 32
Tieing together loose ends: telomere instability in cancer and aging
Borges, G. D. O., Criqui, M., & Harrington, L. A. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13299 · Cited by 34
ESTABROOKS, S. L. (2007) · Journal of Shellfish Research · doi:10.2983/0730-8000(2007)26[307:tproti]2.0.co;2 · Cited by 31
Huang, X.-Q., Wang, J., Liu, J.-P., Feng, H., Liu, W.-B., Yan, Q., Liu, Y., Sun, S.-M., Deng, M., Gong, L., et al. (2005) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-0154 · Cited by 31
Analytical Validation of Telomerase Activity for Cancer Early Detection
Jakupciak, J. P., Wang, W., Barker, P. E., Srivastava, S., & Atha, D. H. (2004) · Journal of Molecular Diagnostics · doi:10.1016/s1525-1578(10)60506-5 · Cited by 31
Down-regulation of p21 contributes to apoptosis induced by HPV E6 in human mammary epithelial cells
Fan, X., Liu, Y., & Chen, J. J. (2005) · APOPTOSIS · doi:10.1007/s10495-005-6062-y · Cited by 30
Kovalenko, O. A., Kaplunov, J. M., Herbig, U., Toledo, S. D., Azzam, E. I., & Santos, J. H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010812 · Cited by 30
Targeting human telomerase for cancer therapeutics
Guittat, L., Alberti, P., Gómez, D., Cian, A. D., Pennarun, G., Lemarteleur, T., Belmokhtar, C., Boujemaa‐Paterski, R., Morjani, H., Trentesaux, C., et al. (2004) · Cytotechnology · doi:10.1007/s10616-004-5127-z · Cited by 34
Zhang, X., Chen, Z., Chen, Y., & Tong, T. (2003) · Oncogene · doi:10.1038/sj.onc.1206317 · Cited by 30
Telomerase-based immunotherapy of cancer
Carpenter, E. L., & Vonderheide, R. H. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.10.1031 · Cited by 30
Cerone, M. A., Londoño‐Vallejo, A., & Autexier, C. (2006) · Oncogene · doi:10.1038/sj.onc.1209727 · Cited by 30
Peptide nucleic acids as antibacterial agents via the antisense principle
Nielsen, P. E. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.2.331 · Cited by 29
Ellipilli, S., Murthy, R. V., & Ganesh, K. N. (2015) · Chemical Communications · doi:10.1039/c5cc05342k · Cited by 28
Atomic-scale structures and interactions between the guanine quartet and potassium
Xu, W., Tan, Q., Yu, M., Sun, Q., Kong, H., Lægsgaard, E., Stensgaard, I., Kjems, J., Wang, J., Wang, C., et al. (2013) · Chemical Communications · doi:10.1039/c3cc43302a · Cited by 28
Means to the ends: The role of telomeres and telomere processing machinery in metastasis
Robinson, N. J., & Schiemann, W. P. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.10.005 · Cited by 28
Telomere lengthening in telomerase-negative cells: the ends are coming together
Scheel, C., & Poremba, C. (2002) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-002-0634-9 · Cited by 28
Toaldo, C., Pizzimenti, S., Cerbone, A., Pettazzoni, P., Menegatti, E., Berardi, D., Minelli, R., Giglioni, B., Dianzani, M. U., Ferretti, C., et al. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00966.x · Cited by 28
Real-Time Determination of Telomerase Activity in Cell Extracts Using an Optical Biosensor
Schmidt, P. M., Matthes, E., Scheller, F. W., Bienert, M., Lehmann, C., Ehrlich, A., & Bier, F. F. (2002) · Biological Chemistry · doi:10.1515/bc.2002.186 · Cited by 27
Reconstitution of hTERT restores tumorigenicity in melanoma-derived c-Myc low-expressing clones
Biroccio, A., Amodei, S., Benassi, B., Scarsella, M., Cianciulli, A. M., Mottolese, M., Bufalo, D. D., Leonetti, C., & Zupi, G. (2002) · Oncogene · doi:10.1038/sj.onc.1205415 · Cited by 27
Patented therapeutic approaches targeting LRP/LR for cancer treatment
Vania, L., Morris, G., Otgaar, T. C., Bignoux, M. J., Bernert, M., Burns, J., Gabathuse, A., Singh, E., Ferreira, E., & Weiss, S. F. T. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1693543 · Cited by 26
Metadata
- Authors
- Herbert, B.-S., Pitts, A. E., Baker, S. I., Hamilton, S. E., Wright, W. E., Shay, J. W., & Corey, D. R.
- Affiliations
- Howard Hughes Medical Institute (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 1999-12-07
- Volume
- 96
- Issue
- 25
- Pages
- 14276-14281
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC24427
- OpenAlex
- W2118228848
- Cited by
- 539
- References
- 48
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 5 · 2023: 7 · 2022: 5 · 2021: 6 · 2020: 5 · 2019: 11 · 2018: 9 · 2017: 9 · 2016: 5 · 2015: 18 · 2014: 7 · 2013: 12 · 2012: 13
- FWCI
- 27.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Ellison Medical Foundation
- National Institutes of Health
- National Cancer Institute (CA 74908, R01CA074908, CA-85143)
- National Institute of General Medical Sciences (T32GM007062, T32GM07062-23)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- telomerase inhibition, telomere shortening, apoptosis, peptide nucleic acid, 2'-O-methyl RNA, breast epithelial cells, cell immortalization, anticancer drug targets
- MeSH terms
- Antineoplastic Agents, Cell Division, Enzyme Inhibitors, Humans, Oligonucleotides, Telomere, Cell Death, Telomerase, Peptide Nucleic Acids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
